BIOSECURE Act: Companies turn to US manufacturers
During Covid-19, US companies had to find onshore manufacturing. Experts believe this may also be an answer to the BIOSECURE Act.
Manufacturing
Build or buy? Key considerations for in-house manufacturing
Theragent to act as partner for CellVax’s Phase II cancer therapy
Instil Bio halts subject enrolment in trials due to manufacturing issues
Russia sanctions: what next for Sputnik Covid-19 vaccine production around the world?
Myelofibrosis market to see new approvals in 2022, driving market growth
UNION’s orismilast enters Phase IIb and a crowded small molecule market
Is precision medicine the future of obesity treatment?
